ALT

ALT R&D to Revenue

162029.27%Fiscal year

Period ending:

ALT FY R&D/Revenue%
ALT FY R&D/Revenue472913.48%-165515.84%
2005-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

ALT r&d to revenue history

R&D spending as percentage of revenue. The available annual fiscal periods series contains 21 observations from Dec 31, 2005 to Dec 31, 2025.

Altimmune Inc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
162,029.2683%
411,130%
15,445.7746%
-103,732.3529%
1,690.2721%
608.1144%
306.2287%
178.6759%
44,349.394%
92.4637%
48.2443%
91.4587%
85.3597%
77.4933%
87.4459%
99.4376%
109.6907%
96.661%
113.0846%
0%
0%

Compare r&d to revenue

All ALT financial metrics · ALT stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.